Cancer staging systems play a vital role in determining appropriate treatments and predicting prognosis for individual patients. In hepatocellular carcinoma (HCC), multiple staging systems have been proposed over the past two decades, but none have gained universal acceptance. Each system is based on the characteristics of the specific patient population studied, taking into account geographic and institutional variations, risk factors, treatment approaches, and healthcare accessibility. The heterogeneity of HCC tumors further adds to the complexity. While a staging system may be effective in one region, it may not be applicable to another. External validation of proposed systems across diverse patient groups is essential to establish a common guideline for HCC management. Various Staging systems present for HCC are as follows: